

FOR DISCUSSION PURPOSES ONLY**USSN 10/814,025 – Draft Claims**

1-47. (Cancelled)

48-59. (Withdrawn)

60. (Currently Amended) A composition comprising human glucocerebrosidase produced according to ~~a the method of claim 48~~ comprising the steps of:

- a. providing a culture of mammalian cells capable of expressing human glucocerebrosidase;
- b. treating said cells with an inhibitor of carbohydrate processing that acts to inhibit the conversion of Glc₃Man₉GlcNac₂ to smaller species; and
- c. recovering the human glucocerebrosidase from the medium of said culture, wherein said recovered human glucocerebrosidase contains a higher number of exposed mannose residues than does human placental glucocerebrosidase.

61. (Currently Amended) A pharmaceutical composition useful for the treatment of a human patient having Gaucher's Disease comprising human glucocerebrosidase containing a higher number of exposed mannose residues than human placental glucocerebrosidase, wherein said glucocerebrosidase is produced by treating cells expressing human glucocerebrosidase with an inhibitor of carbohydrate processing that acts to inhibit the conversion of Glc₃Man₉GlcNac₂ to smaller species.

62. (Previously Presented) The pharmaceutical composition of claim 61, wherein said inhibitor is deoxy-mannoirimycin.

63-72. (Withdrawn)